Journal of Cardiac Failure

Editor's Page: The Future of the Journal of Cardiac Failure: A Reinvigorated Focus on People, Partnerships and Presentation. @dranulala @robmentz onlinejcf.com/article/S1071-…

Check out the editorial: 1️⃣Lp(a) check identifies pts at ⬆️ risk of CV death or HF hosp🏥 (even accounting for NT-proBNP 🧪) 2️⃣Lp(a)+NT-proBNP ⚖️ = better risk stratification 3️⃣Lp(a)>50 mg/dL 💊📈 = consider aggressive lipid-lowering & closer follow-up 🔗 bit.ly/46ZIofV

🧬Lp(a) predicts new-onset HF but does it matter in chronic HF? In >1K HF pts, Lp(a) ≥30 mg/dL was linked to a 35% ⬆️ risk of CV death or HF hosp🏥, independent of NT-proBNP. The signal was stronger in ischemic HF. ⚠️High Lp(a)+NT-proBNP = highest-risk bit.ly/4cBlbEv

Heart transplantation is entering a new era — shaped by innovation, data, and clinical insight. JCF invites submissions for a dedicated Focus Issue on Innovations in Heart Transplantation. 📅 Deadline: April 10, 2026. #CallForPapers #HeartTransplantation #Cardiology

@HFSA @crfheart @robmentz @MaryjaneFarrMD

📍 Filmed at -#THT2026 🤝 In collaboration with Cardiovascular Research Foundation @CRF and Heart Failure Society of America @HFSA #HeartFailure #AdvancedHF #JCardFail

Dr. Mentz has a timely and fascinating conversation with Dr. Farr on the present and future of heart transplantation with DCD hearts at the Technology and Heart Failure Therapeutics (#THT2026) Meeting.

@HFSA @crfheart @robmentz

📍Filmed at -#THT2026 🤝 In collaboration with Cardiovascular Research Foundation @CRF and Heart Failure Society of America @HFSA #HeartFailure #AdvancedHF #LVAD #JCardFail

At the Technology and Heart Failure Therapeutics (#THT2026) Meeting, Co-EIC Dr. Mentz connected with Dr. Cowger to hear her thoughts on next generation LVAD technology and what it will take for a truly game changing advancement. 🧵👇

From predictive analytics to clinical decision support, AI is reshaping heart failure care. Submit your research to JCF’s Focus Issue: Artificial Intelligence & Heart Failure: A Critical Juncture. 🗓️ Due May 10, 2026 bit.ly/4kJl5gf #HeartFailure #AIinHealthcare

📍 Filmed at -#THT2026 🤝 In collaboration with Cardiovascular Research Foundation @CRF and Heart Failure Society of America @HFSA #HeartFailure #AdvancedHF #JCardFail @HFSA @crfheart @ShashankSinhaMD @NirUrielMD

Hot take at at the Technology and Heart Failure Therapeutics (#THT2026) Meeting: How will ML/AI change your day-to-day practice for HF patients? Dr. Nir Uriel explains his approach to implementation and issues call for papers for JCF focus issue due May 10, 2026! 🧵👇

Call for Papers 🚨 Focus Issue: Innovations in Heart Transplantation JCF’s upcoming focus issue will examine the breakthroughs reshaping heart transplantation today. Submit your research by April 10, 2026. #CallForPapers #HeartTransplantation #Cardiology

🤝 In collaboration with @crfheart and @HFSA @robmentz @AshishCorrea @elenadonaldMD @AndrewJSauer @ShashankSinhaMD @DrMarthaGulati #AdvancedHF #LVAD #Xenotransplantation #JCardFail

A powerful reminder that the future of heart replacement therapy will depend not only on scientific breakthroughs, but also on equitable access to the therapies already available. 📍Filmed at #THT2026 🧵👇

At the Technology and Heart Failure Therapeutics (#THT2026) Meeting, co-EIC @dranulala sat down with Mandeep Mehra for a rapid 2-minute JCF soundbite on the evolving landscape of advanced heart failure therapies. 🧵👇

🫀#THTSimPub Alert This 🔥State-of-the-Art Review examines HeartLogic, a multisensor algorithm embedded in existing CIEDs to detect early HF decompensation, as well as the DANLOGIC-HF RCT which will test whether guided management reduces HF events! 🔗 bit.ly/46D91Hv

🫀#THT2026 Sim Pub Alert🚨: A medically-trained LLM #AI model integrated within a health system EMR accurately screened pts for a rare ATTR-CM trial, providing eligibility justifications & improving diversity vs routine workflows. 🔗 bit.ly/4u8aAar

🫀🚨 #THTSimPub Alert! ✅In >25K HF pts, higher GDMT scores were linked to ⬇️ mortality & hospitalization across EF, including HFmrEF & HFpEF. ✅ARNI showed benefit vs ACEi/ARB across EF groups. ✅Time to rethink GDMT in non-HFrEF populations? 🔗 bit.ly/3PftpII